Abstract

Chemokines are small peptides that are potent activators and chemoattractants for leukocyte subpopulations and some nonhemopoietic cells. Their actions are mediated by a family of 7-transmembrane G-protein–coupled receptors, the size of which has grown considerably in recent years and now includes 18 members. Chemokine receptor expression on different cell types and their binding and response to specific chemokines are highly variable. Significant advances have been made in understanding the regulation of chemokine receptor expression and the intracellular signaling mechanisms used in bringing about cell activation. Chemokine receptors have also recently been implicated in several disease states including allergy, psoriasis, atherosclerosis, and malaria. However, most fascinating has been the observation that some of these receptors are used by human immunodeficiency virus type 1 in gaining entry into permissive cells. This review will discuss structural and functional aspects of chemokine receptor biology and will consider the roles these receptors play in inflammation and in infectious diseases.

Phagocytic leukocytes of the immune system undergo rapid and directed movements in chemoattractant gradients, a property that enables them to serve as the first line of cell-mediated host defense against infection. The interaction of chemoattractants with leukocytes initiates a series of coordinated biochemical and cellular events that includes alterations in ion fluxes, integrin avidity and transmembrane potential, changes in cell shape, secretion of lysosomal enzymes, production of superoxide anions, and enhanced locomotion.

Two groups of chemoattractants have been identified and extensively studied. The “classical” chemoattractants, such as bacterial-derived N-formyl peptides, complement fragment peptides C5a and C3a, and lipid molecules such as leukotriene B4 and platelet-activating factor are all chemoattractants and activators of leukocytes.1-4 Recently, a number of chemotactic cytokines in the 8- to 17-kd molecular mass range have been shown to be selective chemoattractants for leukocyte subpopulations in vitro and to elicit the accumulation of inflammatory cells in vivo.5,6 These chemotactic cytokines belong to the chemokine superfamily, which can be divided into 4 groups (CXC, CX3C, CC, and C) according to the positioning of the first 2 closely paired and highly conserved cysteines of the amino acid sequence.

The specific effects of chemokines on their target cells are mediated by members of a family of 7-transmembrane–spanning, G-protein–coupled receptors.7 These chemokine receptors are part of a much bigger superfamily of G-protein–coupled receptors that include receptors for hormones, neurotransmitters, paracrine substances, inflammatory mediators, certain proteinases, taste and odorant molecules, and even photons and calcium ions.8 

To date 18 human chemokine receptors have been identified (Table1). Among the 5 receptors that selectively bind certain CXC chemokines are chemokine receptors CXCR1 to CXCR5, whereas the CC receptor family consists of 9 receptors, CCR1 to CCR9. A further receptor, designated D6, has been termed CCR10 by 1 research group, but this has yet to be officially adopted. Recently, receptors for fractalkine (CX3CR1) and lymphotactin (XCR1) have been identified. A further chemokine receptor, known as the Duffy antigen receptor for chemokines (DARC) has been shown to bind promiscuously to both CXC and CC chemokines. This review describes the characteristics of chemokine receptor gene and protein structure and includes a synopsis of each chemokine receptor identified to date. The roles that chemokine receptors play in inflammation and human disease states are then discussed.

Table 1.

Details of human chemokine receptors described until June 1999

Receptor  Amino acids  Base pairs  Ligand (high affinity) Cellular distribution  
XCR1 (GPR5)  333   999 Lymphotactin  T, B, NK  
CXCR1 (IL8RA)  350  1050 IL8, GCP-2  N, M, T, NK, Bs, Ms, En  
CXCR2 (IL8RB)  355  1065  IL8, GRO-α, GRO-β, GRO-γ, NAP-2, ENA-78, GCP-2  N, M, T, NK, MS, As, Nn, Ms, En 
CXCR3  368  1104  IP-10, Mig, I-TAC  Activated T 
CXCR4* (LESTR, FUSIN)  352  1056  SDF-1α, SDF-1β Myeloid, T, B, Ep, En, DC  
CXCR5 (BLR1)  372 1116  BCA-1  B  
CX3CR1 (V28)  355  1065 Fractalkine  NK, M, T  
CCR1  355  1065  RANTES, MIP-1α, HCC-1, MCP-2, MCP-3, MIP-5, Ckβ8, N, M, T, NK, B, Ms, As, Nn  
CCR2A  374 1122  MCP-1, MCP-3, MCP-4  M  
CCR2B 360  1080 MCP-1, MCP-2, MCP-3, MCP-4  M, T, B, Bs  
CCR3 355 1065  Eotaxin, Eotaxin-2, Eotaxin-3, RANTES, MCP-2,3,4, MIP-5,  Eo, Bs, T  
CCR4  360  1080  TARC, MDC  T, P  
CCR5 (ChemR13)  352  1056  RANTES, MIP-1β, MIP-1α, MCP-2  T, M, M∅︀, DC  
CCR6 (STRL 22, DRY-6, GPR-CY4, CKR-L3)  374  1122  MIP-3α  T, B, DC  
CCR7 (BRL2, EBI1)  378  1134  MIP-3β, 6-C-kine, T, B, DC  
CCR8*, (TER1, CKR-L1, ChemR1)  355  1065 I-309  M, Thymus  
CCR9 (GPR-9-6)  369  1107  TECK T, Thymus  
D6 (CCR10?)  384  1152  MCP-1, MCP-3 placenta, liver  
DARC (Duffy antigen)  338  1014  IL-8, GRO-α, RANTES, MCP-1, MCP-3, MCP-4, Eotaxin  En, RBC, T 
Receptor  Amino acids  Base pairs  Ligand (high affinity) Cellular distribution  
XCR1 (GPR5)  333   999 Lymphotactin  T, B, NK  
CXCR1 (IL8RA)  350  1050 IL8, GCP-2  N, M, T, NK, Bs, Ms, En  
CXCR2 (IL8RB)  355  1065  IL8, GRO-α, GRO-β, GRO-γ, NAP-2, ENA-78, GCP-2  N, M, T, NK, MS, As, Nn, Ms, En 
CXCR3  368  1104  IP-10, Mig, I-TAC  Activated T 
CXCR4* (LESTR, FUSIN)  352  1056  SDF-1α, SDF-1β Myeloid, T, B, Ep, En, DC  
CXCR5 (BLR1)  372 1116  BCA-1  B  
CX3CR1 (V28)  355  1065 Fractalkine  NK, M, T  
CCR1  355  1065  RANTES, MIP-1α, HCC-1, MCP-2, MCP-3, MIP-5, Ckβ8, N, M, T, NK, B, Ms, As, Nn  
CCR2A  374 1122  MCP-1, MCP-3, MCP-4  M  
CCR2B 360  1080 MCP-1, MCP-2, MCP-3, MCP-4  M, T, B, Bs  
CCR3 355 1065  Eotaxin, Eotaxin-2, Eotaxin-3, RANTES, MCP-2,3,4, MIP-5,  Eo, Bs, T  
CCR4  360  1080  TARC, MDC  T, P  
CCR5 (ChemR13)  352  1056  RANTES, MIP-1β, MIP-1α, MCP-2  T, M, M∅︀, DC  
CCR6 (STRL 22, DRY-6, GPR-CY4, CKR-L3)  374  1122  MIP-3α  T, B, DC  
CCR7 (BRL2, EBI1)  378  1134  MIP-3β, 6-C-kine, T, B, DC  
CCR8*, (TER1, CKR-L1, ChemR1)  355  1065 I-309  M, Thymus  
CCR9 (GPR-9-6)  369  1107  TECK T, Thymus  
D6 (CCR10?)  384  1152  MCP-1, MCP-3 placenta, liver  
DARC (Duffy antigen)  338  1014  IL-8, GRO-α, RANTES, MCP-1, MCP-3, MCP-4, Eotaxin  En, RBC, T 
*

T-lymphocyte[en]tropic HIV-1 coreceptor.

Macrophage-tropic HIV-1 coreceptor.

Previous chemokine receptor names are given in brackets.

N, neutrophil; M, monocyte/macrophage; T, T-lymphocyte; B, B-lymphocyte; NK, natural killer cell; Eo, eosinophil; Bs, basophil; Ms, mast cell; As, astrocyte; Nn, neurone; P, platelet; En, endothelial cell; Ep, epithelial cell; Hp, hepatocyte; DC, dendritic cell; M∅︀, macrophage; RBC, erythrocyte.

Structural features of chemokine receptors

All chemokine receptors identified thus far are membrane-bound molecules composed of 7-transmembrane domains and coupled to G-proteins. Figure 1 shows a diagrammatic representation of CXCR1 that provides a good example for discussing the general chemokine receptor structure. Major hallmarks of chemokine receptors are as follows. They measure approximately 350 amino acids in length and require the introduction of few gaps in the primary sequence to be aligned to other chemokine receptors; a short extracellular N-terminus is acidic overall and may be sulfated on tyrosine residues and contain N-linked glycosylation sites; an intracellular C-terminus contains serine and threonine residues that act as phosphorylation sites for receptor regulation; 7 α-helical transmembrane domains—with 3 intracellular and 3 extracellular connecting loops composed of hydrophilic amino acids—are oriented perpendicularly to the plasma membrane; a disulfide bond links highly conserved cysteines in extracellular loops 1 and 2; G-proteins are coupled through the C-terminus segment and possibly through the third intracellular loop.

Fig. 1.

Diagrammatic representation of the chemokine receptor CXCR1.

Extracellular N-terminal acidic residues are shaded, C-terminal potential phosphorylation residues (serine and threonine) are black, and conserved cysteines are hatched.

Fig. 1.

Diagrammatic representation of the chemokine receptor CXCR1.

Extracellular N-terminal acidic residues are shaded, C-terminal potential phosphorylation residues (serine and threonine) are black, and conserved cysteines are hatched.

Human chemokine receptors

CXCR1 and CXCR2

The presence of IL-8 receptors on the surface of granulocytes was first shown by Peveri et al,9 who demonstrated that neutrophils stimulated with either fMLP, C5a, platelet-activating factor, or leukotriene B4 remain responsive to IL-8. It was further reported that sodium iodide I 125–IL-8 specifically bound human neutrophils with 2 affinities; consequently, the presence of 2 IL-8 receptors was postulated, 1 with a high affinity and 1 with a low affinity.10 Conflicting evidence was presented by Samanta et al11 and Grob et al,12who separately described single high-affinity binding sites on human neutrophils. Using chemokine competition experiments, 2 classes of IL-8 binding sites were detected, 1 of which bound NAP-2 and GRO with high affinity and 1 of which bound these chemokines with low affinity. Both classes of receptor, however, had high affinity for IL-8.13,14 The debate concerning the IL-8 binding sites was finally resolved by the cloning of 2 receptors for IL-8, CXCR1, and CXCR2.

CXCR1 (Figure 1) was first cloned by Holmes and colleagues.15 The CXCR1 cDNA contains an open reading frame encoding a protein of 350 amino acids, an N-linked glycosylation site at the N-terminus, and all the other hallmarks of a 7-transmembrane G-protein–coupled receptor. CXCR2 was simultaneously cloned by Murphy and Tiffany16 and was found to be 77% homologous to CXCR1. The CXC chemokines NAP-2, ENA-78, and GRO all bind CXCR2 with high affinity, whereas CXCR1 is selective for IL-8 only.17Recently, CXCR1 and CXCR2 were shown to bind GCP-2.18 Thus, together CXCR1 and CXCR2 bind all known N-terminal Glu-Leu-Arg (ELR)–containing CXC chemokines.

The expression of CXCR1 and CXCR2 on leukocytes has been analyzed using receptor-specific monoclonal antibodies. CXCR1 and CXCR2 are expressed on all granulocytes, monocytes, and mast cells and on some CD8+ T-cells and CD56+ natural killer (NK) cells.19 Equal amounts of CXCR1 and CXCR2 are present on neutrophils, but it appears that monocytes and positive lymphocytes express more CXCR2 than CXCR1.19 Binding of IL-8 to neutrophils rapidly down-regulates CXCR1 and CXCR2 expression by internalization, which is followed by proteolytic degradation of IL-8 by lysosomal enzymes. The receptors are then recycled back to the surface of the neutrophil cell membrane.20 The processes of receptor internalization and recycling are thought to operate for all chemokine receptors identified so far. Tumor necrosis factor and lipopolysaccharide have been shown to down-regulate the expression of both IL-8 receptors on neutrophils by activating a tyrosine kinase-dependent signaling pathway that leads to receptor proteolytic cleavage by metalloproteinases.21Granulocyte–colony-stimulating factor and the bacterial-derived molecule fMLP appear to increase the cell-surface expression of CXCR1 and CXCR2 on neutrophils.22,23 

CXCR3

A human chemokine receptor that is selective for the non-ELR-containing CXC chemokines, IP-10, and Mig has been cloned, and, in accordance with other chemokine receptors, has been named CXCR3.24 The receptor shares 41% identical amino acids with CXCR1 and CXCR2 and is highly expressed on IL-2–activated T lymphocytes but not in resting T cells, B cells, monocytes, or granulocytes.24 Thus, CXCR3 seems to be involved in the selective recruitment of T cells. These data are in accordance with previous results showing that IP-10 and Mig are chemoattractants for T lymphocytes, not granulocytes.25,26 Recently, activated T cells have been shown to bind specifically and to respond to the newly described non-ELR CXC chemokine, I-TAC (interferon-inducible T-cell (chemoattractant) by CXCR3.27 

CXCR4

CXCR4 was originally cloned by Loetscher et al28 as an orphan chemokine receptor (that is, a receptor whose ligand has not yet been discovered) and was given the acronym LESTR. The orphan receptor was found to be expressed on neutrophils, myeloid cells, and, in particular, T lymphocytes.28 LESTR was later identified as an essential cofactor for T-tropic human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) env-mediated fusion and entry into CD4+-expressing cells.29 However, it was not until the CXC chemokine SDF-1 was recognized as the biologic ligand for LESTR that the receptor was reclassified as CXCR4.30,31SDF-1α is a highly efficacious lymphocyte chemoattractant, and it inhibits HIV-1 infection of permissive CD4+ in accordance with CXCR4 expression patterns.30,31 Recently, IL-4 was found to enhance the cell-surface expression of CXCR4 on resting T-cells, whereas the receptor is down-regulated after T-cell stimulation by CD28 or CD3 and CD2.32 Mice lacking the CXCR4 gene exhibit impaired B lymphopoiesis, myelopoiesis, hematopoiesis, derailed cerebellar neurone migration, and defective formation of large vessels supplying the gastrointestinal tract.33-35 These findings suggest that SDF-1 and CXCR4 have biologic functions significantly different from those of other chemokines and chemokine receptors.

CXCR5

The orphan receptor BLR1, which is known to be highly expressed in Burkitt's lymphoma cells and B lymphocytes, was found to have significant homology with other CXC chemokine receptors.36 However, at the time no known CXC chemokines that stimulated B cells had been identified. Legler et al37recently identified and cloned a novel CXC chemokine with potent B-cell–activating capabilities that has subsequently been termed BCA-1 (B-cell–activating chemokine). Furthermore, on screening BCA-1 against a panel of putative chemokine receptors, the chemokine was found to be highly specific for BLR1.37 Consequently, because BLR1 is the fifth CXC chemokine receptor to be identified, it has been renamed CXCR5.

CX3CR1

Fractalkine, a novel class of chemokine with a unique CX3C motif, has been identified and characterized.38 Unlike other chemokines, the molecule exists as a membrane-bound glycoprotein with the chemokine atop an extended mucin-like stalk. Imai et al39 observed that fractalkine bound with high affinity to the orphan chemokine receptor V28 and subsequently renamed the V28 receptor CX3CR1.39 Fractalkine, either attached or detached from its stalk, binds to CX3CR1 and promotes adhesion of monocytes, NK cells, and T lymphocytes to endothelial, epithelial, and dendritic cells.38,40,41 

CCR1

The high-affinity RANTES/MIP-1α receptor (now termed CCR1), which was first cloned by Neote et al42 has 33% similarity to CXCR2 and 31% to CXCR1. It is also 33% homologous to the 7-transmembrane cytomegalovirus protein, US28.43 Indeed, US28 can bind both RANTES and MIP-1α with high affinity, suggesting that US28 may be a CCR1 homologue acquired by viral hijack.44,Xenopus oocytes injected with CCR1 cRNA acquired responsiveness to MIP-1α and RANTES but not to MIP-1β or any other CC chemokine tested.42 Cells transfected with CCR1 responded to MIP-1α, RANTES, MCP-2, and MCP-3; hence, CCR1 also binds MCP-2 and MCP-3.45-47 Recently, the novel CC chemokines MIP-5, HCC-1 (hemofiltrate CC chemokine), and CKβ8 have also been shown to bind specifically to CCR1.48,49 

Lipopolysaccharide caused a rapid reduction of CCR1 mRNA levels in monocytes, leading to a reduced cellular response to ligand-specific chemokines,50 whereas monocytoid U937 cells and neutrophils stimulated with interferon exhibited increased mRNA and cell-surface expression of CCR1.51,52 IL-2 and IL-15 induced the expression of CCR1 on activated T cells,53,54 whereas IL-10 selectively up-regulated the expression of CCR1 in human monocytes by prolonging mRNA half-life.55 

CCR2A and CCR2B

The monocyte chemotactic proteins function as potent activators and chemoattractants for monocytes, basophils, eosinophils, and T-lymphocyte subsets, but not for neutrophils.5 Direct binding studies with 125I–MCP-1 identified high-affinity binding sites on human monocytes.56 Monocyte, basophil, and eosinophil activation by CC chemokines, including MCP-1, are prevented by pretreatment with Bordetella pertussis toxin, suggesting that the action of MCP-1 is mediated by a G-protein–coupled receptor.57 

Two independent groups simultaneously cloned CCR2. Yamagami et al58 identified CCR2B, which encodes a protein of 360 amino acids and has 56% similarity to CCR1. Cloning by Charo et al59 produced 2 positive clones corresponding to 2 forms of CCR2—CCR2A and CCR2B. Both CCR2A and CCR2B have identical 5′ untranslated and transmembrane regions, but they differ in an alternatively spliced carboxyl terminus. Consequently, the carboxy tail of CCR2B is 36% homologous to the corresponding region in CCR1, whereas the carboxy tail of CCR2A bears no similarities to any other known chemokine receptor.59 Recent studies record that MCP-2, MCP-3, and MCP-4 can also bind to CCR2B.46,47 The expression of CCR2 mRNA in monocytes has been found to be decreased by both IFN-γ60 and lipopolysaccharide,50whereas IL-2 induced the expression of CCR2 in T lymphocytes, which correlated with the response of these cells to MCP-1 in chemotaxis assays.53 Furthermore, IL-10 selectively up-regulated the expression of CCR2 in monocytes by prolonging the mRNA half-life.55 

CCR3

Cross-desensitization experiments using chemokine-induced intracellular calcium mobilization have indicated that eosinophils may have specific receptors for RANTES, MCP-3, and eotaxin and a shared receptor for MIP-1α, RANTES, and MCP-3.61,62 MIP-1α, RANTES, and MCP-3 can bind to CCR1, and MCP-3 can also bind to CCR2; however, CCR2 is not expressed by eosinophils. Using this information, Daugherty et al63 and Kitaura et al64independently identified and characterized the eosinophil-selective chemokine receptor CCR3. CCR3 cDNA encodes for a protein that is expressed predominantly on eosinophils but can also be detected on basophils and T cells.63,65,66 The receptor has 63% similarity to CCR1 and 51% to CCR2B and binds several CC chemokines specifically, including eotaxin, eotaxin-2, RANTES, MCP-3, MCP-4, and MIP-5, all of which have been implicated in eosinophil recruitment and activation.63,65,67 Eotaxin and eotaxin-2 have the greatest affinity for CCR3 and, accordingly, are the most potent chemokine activators of eosinophils.68 Subsequently, CCR3 has been implicated in the progression of allergic reactions (discussed below). In association with CD4, CCR3 has also been implicated in permitting macrophage-tropic HIV-1 infection of permissive cells.69 

CCR4

Power et al70 have identified a novel CC chemokine receptor called CCR4 that shares 49% identity with CCR1 and 47% with CCR2B.70 Initially, it was thought that CCR4 bound RANTES and MIP-1α. However, recent studies show that CCR4 specifically binds the CC chemokines TARC (thymus and activation-regulated chemokine) and MDC (macrophage-derived chemokine).71,72 TARC and MDC have both been shown to be selective activators of T lymphocytes, particularly CD4+ Th2 cells. These data are in agreement with the expression of CCR4, which appears to be highly expressed in T lymphocytes and platelets and weakly expressed in other peripheral mononuclear cells.70,71 Furthermore, the expression of CCR4 on Th2 cells was transiently increased after T-cell receptor and CD28 engagement. Consequently, the activity of Th2 cells to TARC was enhanced on receptor activation.73 

CCR5

Originally cloned by Samson et al,74 CCR5 was found to bind the CC chemokines MIP-1β, RANTES, MIP-1, and MCP-2 specifically using transfected and peripheral blood mononuclear cells.75These studies were quickly corroborated by Raport et al,76who also demonstrated CCR5 mRNA expression in lymphoid organs such as the thymus and spleen and in peripheral T lymphocytes and macrophages.76 CCR5 is most closely related to CCR2B, with 71% identical amino acid residues. Furthermore, the gene encoding CCR5 is a localized only 18-kb pair downstream of the gene for CCR2 on chromosome 3p21,74,76 which suggest that these 2 receptors share an ancestral gene. CCR5 is also homologous to other CC receptors and shares 55%, 49%, and 48% identity with CCR1, CCR3, and CCR4, respectively.76 Recently, CCR5 has been shown to be the major coreceptor in association with CD4 for macrophage-tropic HIV-1 entry into permissive cells.69 The immunosuppressive and anti-inflammatory cytokine IL-10 selectively up-regulated the expression of CCR5 in human monocytes by prolonging the mRNA half-life.55 It appears that this increase in CCR5 expression is regulated by activation of MAP and STAT kinases.77 IL-15–stimulated T cells also increased their expression of CCR5,54 indicating that interleukins can act as modulators of chemokine receptor expression.

CCR6

CCR6 was originally cloned by several groups as an orphan chemokine receptor and was therefore provided with several different acronyms (STRL 22, DRY-6, GPR-CY4, CKR-L3). It was not until Baba et al78 discovered that the CC chemokine MIP-3α/LARC (liver and activation-regulated chemokine) specifically bound to the orphan receptor GPR-CY4 that these orphan receptors were all redesignated as CCR6. CCR6 has been detected on memory T cells, B lymphocytes, and dendritic cells but not on any other peripheral blood leukocyte.79 CCR6 mRNA has been shown to be up-regulated by treatment with IL-2.78,80 However, recent data contradict this finding79 and, as a consequence, the effect of IL-2 on CCR6 expression remains uncertain.

CCR7

By searching the expressed sequence tag (EST) database, Yoshida et al81 identified a cDNA sequence that codes for a novel CC chemokine, was termed ELC (EBI1-ligand chemokine) or MIP-3β. ELC was then screened against a panel of cells transfected with known and orphan chemokine receptors to search for its corresponding high-affinity receptor. It was found that ELC bound specifically to the orphan receptor EBI1,82 which has subsequently been renamed CCR7.81 Recently, the novel CC chemokine 6-C-kine, also known as SLC (secondary lymphoid-tissue chemokine), has been shown to be a specific agonist for CCR7.83 CCR7 is known to be expressed on activated T and B lymphocytes and dendritic cells and is strongly up-regulated in B cells infected with Epstein–Barr virus and in T cells infected with herpesvirus 6 or 7.81,84 

CCR8

The human CC chemokine I-309 is a potent monocyte chemoattractant and inhibits apoptosis in thymic cell lines.85 To identify its cognate chemokine receptor, Roos et al86 used an intracellular calcium mobilization assay with I-309 to test for receptor function in cells transfected with several known orphan receptors. I-309 was found to bind specifically to and to activate cells transfected with the orphan receptor known as either TER1,87 ChemR1,88 or CKR-L1.89These findings were quickly corroborated by Tiffany et al.90 Consequently, these orphan receptors were collectively renamed CCR8, in accordance with the nomenclature system for chemokine receptors. Strong CCR8 mRNA expression was detected in the thymus and monocytes but not in other peripheral blood leukocytes.90 These data appear to be in agreement with the role of I-309 in monocyte activation and thymic cell survival. Indeed, CCR8 is preferentially expressed on Th2-polarized cells91and is transiently increased after T-cell receptor and CD28 engagement,73 suggesting that CCR8 plays a role in the control of Th2 responses and that up-regulation of CCR8 after antigen encounter may contribute to the proper positioning of activated T cells within sites of antigenic challenge or specialized areas of lymphoid tissue.73 Recently, CCR8 has been shown to serve as a cofactor, in association with CD4, to permit the infection of permissive cells with T-cell tropic and macrophage-tropic HIV-1 strains.92 

CCR9

CCR9 is the most recent chemokine receptor to be identified. Zaballos et al93 found that thymus-expressed chemokine (TECK) is a specific agonist for the human orphan receptor GPR-9-6 (EMBL accession number U45 982), which has been renamed CCR9 according to the established nomenclature. CCR9 expression is high in the thymus but low in lymph nodes and spleen, and it appears to be expressed on both immature and mature T cells.93 These data are in agreement with previous results showing that TECK is an activator of dendritic cells and thymocytes, which implicates this CC chemokine in T-cell development.94 

D6 (CCR10?)

D6 was simultaneously cloned by 2 independent groups and displays approximately 30% homology with other CC chemokine receptors at the amino acid level.95,96 It was originally described by Bonini et al95 as CCR10. However, because D6 does not generate an intracellular signal on ligand binding and, therefore, appears not to be functional,96 the receptor has yet to be granted a CCR number. The ligand specificity of D6 is also contentious. Bonini et al95 reported D6 to bind MCP-1 and MCP-3 with high affinity, whereas Nibbs et al96 suggest that D6 is more promiscuous because it is able to bind a number of CC chemokines with similar affinity. Northern blot analysis of several human tissues reveals that D6 is almost exclusively expressed in placenta with weak expression in the liver, lung, and thyroid.95,96 These data suggest that D6 may have a role in placental immunity or hematopoiesis.

XCR1

Yoshida et al97 have recently reported the finding that the single C motif chemokine lymphotactin binds specifically to the orphan chemokine receptor previously termed GPR5.98 In keeping with the chemokine receptor nomenclature, this receptor has now been designated XCR1. The lymphotactin receptor is strongly expressed in placenta and weakly expressed in spleen and thymus.97Because lymphotactin activity is most pronounced against lymphocytes and NK cells,99,100 it is expected that these leukocyte subpopulations will also express XCR1.

Duffy antigen receptor for chemokines

The transmembrane glycoprotein gpD had long been known to be part of the multimeric protein complex that makes up the antigen for the Duffy blood group system.101,102 However, it was not until Chaudhuri et al103 cloned the cDNA for gpD that it was found to be a 7-transmembrane receptor with significant homology to previously cloned chemokine receptors. This discovery also partly explained the phenomenon that erythrocytes could bind both the CXC chemokine IL-8 and the CC chemokine MCP-1.104,105 DARC (Duffy antigen receptor for chemokines) has also been shown to bind numerous CXC and CC chemokines specifically, including RANTES, I-309, GRO-α, MCP-3, MCP-4, and eotaxin,106 and it has been implicated in the pathogenesis of malaria102 (discussed below).

In addition to erythrocytes, DARC expression has been detected on renal and spleen capillary endothelium,107 endothelial cells of venules,108 and Purkinje cells in the brain.109It is thought that erythrocyte, endothelial, and Purkinje cell binding of CXC and CC chemokines by DARC may limit the stimulation of leukocytes by chemokines released into the bloodstream and that it may also modulate neuronal activity.104,109 DARC is expressed on endothelial cells at anatomic sites of leukocyte trafficking and diapedesis, a process highly regulated by the actions of chemokines that bind to DARC. Whether DARC actually plays a role in leukocyte trafficking remains to be determined. It is of note that DARC-dependent signal transduction has not yet been demonstrated and that DARC does not appear to be coupled to a G-protein.110 Therefore, the precise physiological role of DARC has yet to be elucidated.

Chemokine receptor signal transduction mechanisms

Intracellular signaling by chemokine receptors depends on coupling to Bordetella pertussis toxin-sensitive heterotrimeric G-proteins, usually of the Gi-type (for a more detailed discussion, see Murphy111 and Bokoch112). G-proteins are inactive when GDP is bound to the G-protein subunit, but they become active when GDP is exchanged for GTP. During ligand binding, chemokine receptors associate with G-proteins, facilitating the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP). In the active state, G-proteins dissociate into Gα and Gβ subunits; the latter are able to activate the membrane-associated enzyme phospholipase Cβ2 (PLC2), which in turn cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to form the intracellular second messages phosphatidylinositol 1,4,5-triphosphate (IP3) and diacyl-glycerol (DAG) (Figure 2). IP3 mobilizes calcium from intracellular stores, whereas DAG acts in conjunction with calcium to activate various isoforms of protein kinase C (PKC). The activation of PKC and of various calcium-sensitive protein kinases catalyses protein phosphorylation, which activates a series of coordinated signaling events that eventually lead to cellular responses.111-114 There is increasing evidence that chemokine receptors can also activate several different intracellular effectors downstream of Gicoupling, including the low-molecular-weight proteins Ras and Rho,112,115 phospholipase A2, phosphatidylinositol-3-kinase,116 tyrosine kinases,117-119 and the MAP kinase pathway120(Figure 2). No doubt the precise signaling mechanisms by which all chemokine receptors regulate cellular function will become evident in time.

Fig. 2.

Model of chemokine receptor activation and signal transduction for IL-8 and neutrophils.

IL-8 binding to CXCR1 or CXCR2 causes guanosine triphosphate displacement of guanosine diphosphate in the Gαi2subunit, which allows dissociation of Gαi2 from Gβγ. Gβ activates phospholipase C (PLCβ), which cleaves PIP2 into the second messengers DAG and IP3. DAG activates PKCβ, whereas IP3 causes the release of calcium from intracellular stores. The rapid rise in intracellular calcium activates PLD. Meanwhile Gαi2directly activates PTK. These activate MAP kinases and phosphorylate serine and threonine residues on the C-termini of CXCR1 and CXCR2, leading to receptor inactivation. MAP kinases activate phospholipase A2. DAG, intracellular calcium, PKC, and phospholipase A2 (PLA2) all interact with specific cell activation mechanisms, leading to cell motility, degranulation, release of superoxide anions, and modification of integrin avidity.

Fig. 2.

Model of chemokine receptor activation and signal transduction for IL-8 and neutrophils.

IL-8 binding to CXCR1 or CXCR2 causes guanosine triphosphate displacement of guanosine diphosphate in the Gαi2subunit, which allows dissociation of Gαi2 from Gβγ. Gβ activates phospholipase C (PLCβ), which cleaves PIP2 into the second messengers DAG and IP3. DAG activates PKCβ, whereas IP3 causes the release of calcium from intracellular stores. The rapid rise in intracellular calcium activates PLD. Meanwhile Gαi2directly activates PTK. These activate MAP kinases and phosphorylate serine and threonine residues on the C-termini of CXCR1 and CXCR2, leading to receptor inactivation. MAP kinases activate phospholipase A2. DAG, intracellular calcium, PKC, and phospholipase A2 (PLA2) all interact with specific cell activation mechanisms, leading to cell motility, degranulation, release of superoxide anions, and modification of integrin avidity.

After activation, chemokine receptors become either partially or totally desensitized to repeated stimulation with the same or other agonists. This process is thought to involve phosphorylation of serine and threonine residues in the C-tail of the receptor by G-protein–coupled receptor kinases and receptor sequestration by internalization. Desensitization may be critical for maintaining the capacity of the cell to sense a chemoattractant gradient.111 

Chemokine receptors in inflammation

Leukocyte activation in acute inflammation

To reach sites of inflammation or injury, circulating leukocytes must exit the bloodstream by traversing the endothelium. Leukocytes usually attach to the apical surface of the endothelium of postcapillary venules, where the shear stress is lowest. The first step in the process of leukocyte recruitment at sites of inflammation is the generation of transient selectin-mediated interactions that cause tethering and rolling of flowing leukocytes on the endothelial cell surface.121 The slow velocity of rolling leukocytes on selectins favors encounters with chemokines that are presented on the apical surface of the endothelium by glycosaminoglycans.122Chemokines bind to their respective chemokine receptors expressed on the leukocyte cell surface, leading to the alteration of β2 integrin avidity, especially CD11b/CD18, on the leukocyte cell surface.123 Then β2 integrins bind to their Ig counterligands, such as ICAM-1, ICAM-2, and ICAM-3, which have been up-regulated on the endothelial cell surface by proinflammatory cytokines. These interactions provide firm attachment of leukocytes to the endothelium and facilitate leukocyte haptotactic transendothelial migration.123,124 The binding of chemokines to their respective leukocyte receptors also initiates a series of cellular events, all of which aim to eradicate the infiltrating inflammatory agents. These events include changes in cell shape leading to enhanced locomotion, secretion of lysosomal enzymes, and production of superoxide anions. Once leukocytes reach the source of inflammation, a cytokine-rich milieu is generated that is sustained until the invading antigen is eliminated. In general, immune responses do not produce endothelial injury; however, on occasion acute or chronic inflammation may occur in which the endothelium and surrounding tissues become damaged (for example, by neutrophil-generated products).

Inflammation resolution and inflammatory disorders

After acute infection or injury, blood vessels may be damaged. Part of the mechanism of wound healing, the formation of new blood vessels, known as angiogenesis, is a process tightly regulated by numerous biologic mediators, among them chemokines.125 CXC chemokines, such as IL-8, GRO-α, GRO-β, PF-4, IP-10, and Mig, have been implicated in the regulation of keratinocyte and endothelial cell function, including the stimulation and inhibition of proliferation, angiogenesis, angiostasis, and cell migration.125-131However, evidence concerning the expression of chemokine receptors by endothelial cells has been conflicting.132,133 Recent data now show that endothelial and epithelial cells express several functional chemokine receptors, in particular CXCR4.134-137It has been proposed that endothelial proteoglycans can present chemokines to leukocyte and to endothelial-expressed chemokine receptors.134,136 This model is analogous to the way in which basic fibroblast growth factor is thought to bind to endothelial proteoglycans, facilitating its interaction with high-affinity fibroblast growth factor receptors on the endothelial cell surface.138 A low level of expression and responsiveness of chemokine receptors on endothelial cells may be sufficient to permit cell activation in the presence of high levels of proteoglycan-bound chemokine on the adjacent endothelial cell surface. These findings suggest that chemokines and their receptors may play an important role in the vascular remodeling and maintenance associated with inflammatory resolution and, as a consequence, may be implicated in the development of inflammatory disorders, as discussed below.

Psoriasis

The overproduction of CXC and CC chemokines has been associated with many disease states, including arthritis, multiple sclerosis, and lung disorders such as adult respiratory distress syndrome, idiopathic pulmonary fibrosis, and pneumonia.139-142 It was initially noted that large quantities of IL-8, activated neutrophils, and T lymphocytes were present in the epidermis of patients with psoriasis vulgaris.139 Consequently, IL-8 was shown to induce the expression of HLA-DR and to be chemotactic and mitogenic for keratinocytes.129,132 Furthermore, Schulz et al143 demonstrated that CXCR1 and CXCR2 mRNA levels were 10 times more abundant in lesional psoriatic epidermis than in normal epidermis.143 This has led to the suggestion that the overexpression of IL-8 receptors is responsible for the epidermal hyperplasia, leukocyte infiltration, and increased keratinocyte HLA-DR expression seen in psoriasis. Indeed, antipsoriatic drugs such as calcitriol, dithranol, cyclosporin, and FK 506 have been shown to be potent down-regulators of IL-8 receptors on keratinocytes.143,144 

Atherosclerosis

The recruitment of monocytes and the migration, growth, and activation of lipid-laden macrophages, T lymphocytes, and smooth muscle cells during the development of atherosclerotic plaques are critical features of the chronic inflammatory response that typifies atherosclerosis.145 Early studies by Nelken et al146 showed that the CC chemokine MCP-1 is abundantly expressed in macrophage-rich areas of atherosclerotic plaques, suggesting that MCP-1 may be important for monocyte extravasation and for the formation of atherosclerotic lesions.

Further evidence implicating MCP-1 in the pathogenesis of atherosclerosis has come from transgenic mouse models. Apolipoprotein B/MCP-1–deficient mice that overproduce apolipoprotein B-containing lipoproteins and are therefore susceptible to atherosclerosis are protected from atherosclerotic lesion development even when fed a high-fat diet.147 Furthermore, low-density lipoprotein (LDL) receptor/MCP-1–defective mice on a high-cholesterol diet had 83% less lipid deposition throughout their arteries than controls.148 These genetic data strongly suggest that MCP-1 expression is crucial for the development of atherosclerotic plaques. Similar results have been produced using CCR2 knockout mice also deficient in the apolipoprotein E gene and therefore predisposed to severe atherosclerosis. These double-knockout mice had 50% fewer lesions, indicating that CCR2, which is the major MCP-1 receptor, is also associated with the development of early atherosclerosis.149 Interestingly, monocyte CCR2 expression was dramatically increased in hypercholesteremic patients, and native, but not oxidized, LDL significantly increases monocyte CCR2 expression and chemotaxis activity toward MCP-1.150These data imply that elevated plasma LDL levels enhance monocyte CCR2 expression and activity, contributing to increased monocyte recruitment in atherosclerotic plaques.151 Recent evidence has shown that tissue factor, a protein also found in the atherosclerotic plaques, is expressed by SMC when stimulated with MCP-1.152This can be inhibited by pertussis toxin, but the investigators failed to show CCR2 expression on SMC. However, Hayes et al153have detected the expression of CCR2 and CCR1, but not CCR3-5, by reverse transcription–polymerase chain reaction in primary cultures of SMC. Such observations have been corroborated in our laboratory. We found mRNA expression of CXCR1, CXCR2, CCR1, and CCR2B, but not CCR3-5, in vascular SMC (unpublished data). These data suggest that CCR2 expression on SMC and on monocytes is important for atherosclerosis development.

It is not only MCP-1 and CCR2 that have been implicated in atherosclerosis. Histologic studies show that activated T cells are present throughout all stages of atherosclerotic lesion development.145 Within atherosclerotic plaques, macrophages and intimal SMC express the potent chemotactic T-cell chemokines PARC, ELC, and IP-10.154,155 The latter chemokine, along with IL-8, has also been shown to induce a dose-dependent stimulation of DNA synthesis, cell proliferation, and cell migration of human SMC.155,156 Furthermore, mice lacking human homologue receptors for IL-8 are less susceptible to atherosclerosis and have fewer vascular lesions than mice expressing these receptors.157 Taken together, these data suggest that certain chemokines and their receptors play an important role in modulating the functions of leukocytes and SMC involved in the development and progression of atherosclerosis.

Allergy

Recently, chemokines have been implicated in contributing to allergic disorders, in particular to allergic airway inflammation such as allergic rhinitis and asthma.158-160 The long-term effects of these diseases have been attributed, in part, to the infiltrating leukocytes, in particular eosinophils, that surround the bronchus and infiltrate the airway.161 

The CC chemokines eotaxin, eotaxin-2, and MCP-4—which are released by airway epithelial cells—preferentially attract and activate eosinophils by acting specifically through CCR3.62,68 It has been shown that levels of eotaxin and MCP-4 are substantially elevated in the lungs of persons with asthma and are correlated with the numbers of infiltrating eosinophils, implicating these chemokines in asthmatic lung inflammation.162Recently, Ying et al163 reported that the expression of CCR3 is also elevated significantly in persons with atopic asthma. There is also an increased bone marrow pool of CCR3(+) mature and immature eosinophils available for rapid mobilization to subjects with asthma.164 Thus it appears that CCR3 is substantially involved in the recruitment of inflammatory cells in allergic responses. CCR3 contains 4 nucleotide polymorphisms, 2 of which encode for an amino acid change.165 Selected polymorphisms have been shown to have dramatic effects on the manifestation of or the susceptibility to a variety of diseases. These results may have implications for those with allergic responses such as asthma, which involves CCR3. As a consequence CCR3 may be a prime therapeutic target in the spectrum of allergic diseases involving eosinophil-mediated tissue damage.

T cells with a Th2 cytokine phenotype are also prominent in the pathogenesis of allergic diseases.166 Th2 cells preferentially express CCR4 and CCR8.91 Furthermore, the ligands for these chemokine receptors (TARC, MDC, and I-309) are potent chemoattractants for Th2 cells. These observations suggest that both CCR4 and CCR8 play a role in the control of Th2 responses and may represent potential targets for the treatment of allergic diseases. The induction of experimental allergic encephalomyelitis in the rat was accompanied by increased levels of CCR2, CCR5, CXCR4 and CX3CR1 mRNA in the lumbar spinal cords of animals displaying clinical signs of the disease.167 These findings are strong evidence implicating certain chemokine receptors as mediators of allergic diseases.

Chemokine receptors in infectious diseases

Until recently little attention has been paid to the role of chemokine receptors in infectious diseases. However, it is now known that chemokine receptors participate in several disease states, either by overexpressing receptors or by facilitating viral entry into permissive cells.

Malaria

Malaria is transmitted by mosquitoes infected with 1 of 4 pathogenic parasites. These parasites bind to and invade erythrocytes eventually causing them to undergo cell lysis. It is this stage of the parasitic life cycle that is associated with clinical illness. Malaria is endemic in most tropical and subtropical areas of the world; however, it is much less prevalent in West Africa. In this geographical area, 95% of the population is resistant to the malaria parasites Plasmodium vivax and Plasmodium knowlesi.110 Miller et al168 note that erythrocytes from humans resistant toP. knowlesi infection do not express the Duffy antigen receptor for chemokines (DARC) on their red blood cells. It was subsequently shown that P. vivax could not invade erythrocytes of DARC-negative patients and that an anti-DARC antibody could block parasite invasion into DARC-positive red blood cells.169,170 A number of studies have since revealed that both P. vivax and P. knowlesi gain entry to erythrocytes by binding specifically to DARC.102,110,171The genetic difference between persons who are susceptible to P. vivax and P. knowlesi invasion and those who are not corresponds to a single G-to-A nucleotide substitution, producing a Gly44Asp substitution in the polypeptide chain that prevents parasite invasion into erythrocytes.172,173 Interestingly, in some patients DARC is not expressed on red blood cells at all but is expressed on other cell types, including the endothelium.108 It appears that this phenomenon results from a mutation in the DARC promoter region in the erythrocytes of these patients.174 Whether P. vivax or P. knowlesi can gain entry to other cell types that express DARC has yet to be determined. The physiologic roles of DARC remain only partially elucidated (see section on DARC above).

Human immunodeficiency virus

Perhaps the most exciting development in chemokine receptor-associated pathogenesis comes from the discovery that some chemokines function as HIV-1–suppressive factors.175 Feng et al29 showed that T-cell–tropic HIV-1 isolates used both CD4 and CXCR4 to support Env-mediated cell fusion and HIV-1 infection of permissive cells.29 Further evidence showed that SDF-1 could block HIV-1 entry by binding to CXCR4 expressed by lymphocytes.30,31 These discoveries promoted frantic research in the area of HIV infection. Consequently, it was soon ascertained that CC chemokine receptors CCR2, CCR3, and CCR5 could also serve as cofactors, along with CD4, to permit HIV-1 entry, this time preferentially by macrophage-tropic and dual-tropic strains of HIV-1.69,176-178 Recently, CCR8 has been identified as a cofactor, in association with CD4, to permit the infection of permissive cells either by T-cell tropic or by macrophage-tropic HIV-1 strains.92 

The role chemokine receptors play in permitting HIV-1 viral entry into permissive cells has been extensively reviewed.179-181Entry of HIV-1 into cells is a multistep process mediated by the viral Env protein. Env initially binds the virus particle to CD4, which induces conformational changes in the HIV gp120 subunit, exposing the third variable (V3) loop (Figure 3A). However, these conformational changes cannot generate an Env structure that is fusogenic. The fusion-inducing conformational changes are driven by certain chemokine receptors (Figure 3B, Table 1) that bind to the exposed regions of the V3-loop of gp120.182 Recent evidence suggests that after translation modification, sulfated tyrosines and acidic amino acid residues in the N-terminus of CCR5 and CXCR4 are necessary for binding to gp120 and, thus, for the formation of the HIV-1 gp120/CD4 complex.183-185 The fusogenic complex that results from this chemokine receptor/gp120 interaction comprises a coiled–coil structure in the gp41 ectodomain that displaces the hydrophobic N-terminal domain of the gp41 subunit toward the plasma membrane of the target cell.186 The fusion peptide is likely to insert into the cell membrane, making Env an integral component of the 2 membranes which eventually leads to the insertion of viral DNA into the target cell (Figure 3C). Interestingly, CXCR4 can recognize the T-tropic virus-binding site in the absence of CD4.187 The function of CD4 for these viruses may be merely to concentrate the virus and present it to the chemokine receptor. This may explain why CXCR4 is capable of permitting HIV entry into cells that do not express CD4.187 

Fig. 3.

T-lymphocyte–tropic HIV-1 infection of CXCR4-expressing cells.

(A) The gp120 subunit of an env oligomer binds to CD4, inducing conformational changes including increased exposure of the V3 loop. This enables env to interact with the appropriate coreceptor, in this case CXCR4 (B). This interaction is then proposed to trigger the final conformational changes in env, including the formation of a coiled–coil structure in gp41 that ensures that the fusion peptide inserts into the cell membrane (C).

Fig. 3.

T-lymphocyte–tropic HIV-1 infection of CXCR4-expressing cells.

(A) The gp120 subunit of an env oligomer binds to CD4, inducing conformational changes including increased exposure of the V3 loop. This enables env to interact with the appropriate coreceptor, in this case CXCR4 (B). This interaction is then proposed to trigger the final conformational changes in env, including the formation of a coiled–coil structure in gp41 that ensures that the fusion peptide inserts into the cell membrane (C).

In humans it appears that during the asymptomatic stages of infection, HIV-1 binding to CCR5 predominates.188 However, as infection proceeds, HIV-1 uses other chemokine receptors, particularly CXCR4.29 An important finding for HIV biology was reported in 1996 when Liu et al189 and Samson et al190simultaneously identified a 32-bp deletion of the CCR5 gene that is present at a high frequency in white populations but is absent in African and Japanese populations.189,190 The deletion generates a rapidly degraded, nonfunctional receptor that does not support membrane fusion or infection by macrophage- or dual-tropic HIV-1 strains.189 The mutation can be heterozygous or homozygous; the latter largely protects against the acquisition of CCR5-mediated HIV-1 infection, though homozygosity does not confer absolute protection.191 Polymorphisms other than the 32-bp deletion in chemokine receptors CCR2, CCR3, and CCR5 have also been identified.165,192,193 These genomic defects generate single amino acid substitutions within the chemokine receptor. The consequences of these polymorphisms on HIV infection and pathogenesis have yet to be determined.

Recent evidence suggests that the human T-lymphotropic virus type 1 (HTLV-1) Tax protein up-regulates the cell-surface expression of CXCR4 and CCR5 by interacting with transcription factors causing transactivation of the chemokine receptor gene promoters.194 This finding suggests that HTLV-1 may contribute to the acceleration of HIV disease observed in some coinfected persons.

Summary

There has been rapid recent progress in the understanding of the biology of chemokines and their receptors. This progress has seen an increase in the association between chemokine receptors and certain human disease states. The discovery that chemokine receptors are expressed on nonhemopoietic cell types, such as endothelial and epithelial cells, will almost certainly lead to the receptors being implicated in other biologic and disease processes, such as angiogenesis, organ development, metastasis, and tumorigenesis. Future advances in chemokine receptor biology are certain to follow.

Supported by the Children's Appeal, Sheffield Children's Hospital, Sheffield, United Kingdom.

Reprints:Craig Murdoch, Division of Child Health, University of Sheffield, Sheffield Children's Hospital, Sheffield, S10 2TH, United Kingdom; e-mail: c.murdoch@sheffield.ac.uk.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

References

References
1
Schiffmann
E
Corcoran
BA
Wahl
SM
N-formylmethionyl peptides as chemoattractants for leucocytes.
Proc Natl Acad Sci U S A.
72
1975
1059
2
Gerard
C
Gerard
NP
C5A anaphylatoxin and its seven transmembrane-segment receptor.
Annu Rev Immunol.
12
1994
775
3
Goldman
DW
Goetzl
EJ
Specific binding of leukotriene B4 to receptors on human polymorphonuclear leukocytes.
J Immunol.
129
1982
1600
4
Hanahan
DJ
Platelet activating factor: a biologically active phosphoglyceride.
Annu Rev Biochem.
55
1986
483
5
Baggiolini
M
Dewald
B
Moser
B
Interleukin-8 and related chemotactic cytokines CXC and CC chemokines.
Adv Immunol.
55
1994
97
6
Baggiolini
M
Dewald
B
Moser
B
Human chemokines: an update.
Annu Rev Immunol.
15
1997
675
7
Murphy
PM
The molecular biology of leukocyte chemoattractant receptors.
Annu Rev Immunol.
12
1994
593
8
Watson
B
Arkinstall
S
The G-Protein Linked Receptor Facts Book.
1994
Academic Press
London
9
Peveri
P
Walz
A
Dewald
B
Baggiolini
M
A novel neutrophil-activating factor produced by human mononuclear phagocytes.
J Exp Med.
167
1988
1547
10
Besemer
J
Hujber
A
Kuhn
B
Specific binding, internalization, and degradation of human neutrophil activating factor by human polymorphonuclear leukocytes.
J Biol Chem.
264
1989
17,409
11
Samanta
AK
Oppenheim
JJ
Matsushima
K
Identification and characterization of specific receptors for monocyte-derived neutrophil chemotactic factor (MDNCF) on human neutrophils.
J Exp Med.
169
1989
1185
12
Grob
PM
David
E
Warren
TC
DeLeon
RP
Ferina
PR
Homon
CA
Characterization of a receptor for human monocyte-derived neutrophil chemotactic factor/interleukin-8.
J Biol Chem.
265
1990
8311
13
Moser
B
Schumacher
C
von Tscharner
V
Clark-Lewis
I
Baggiolini
M
Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils.
J Biol Chem.
266
1991
10,666
14
Lee
J
Horuk
R
Rice
GC
Bennett
GL
Camerato
T
Wood
WI
Characterization of two high-affinity human interleukin-8 receptors.
J Biol Chem.
267
1992
16,283
15
Holmes
WE
Lee
J
Kuang
WJ
Rice
GC
Wood
WI
Structure and functional expression of a human interleukin-8 receptor.
Science.
253
1991
1278
16
Murphy
PM
Tiffany
HL
Cloning of complementary DNA encoding a functional human interleukin-8 receptor.
Science.
253
1991
1280
17
Ahuja
SK
Murphy
PM
The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor.
J Biol Chem.
271
1996
20,545
18
Wolf
M
Delgado
MB
Jones
SA
Dewald
B
Clark-Lewis
I
Baggiolini
M
Granulocyte chemotactic protein 2 acts via both IL-8 receptors, CXCR1 and CXCR2.
Eur J Immunol.
28
1998
164
19
Chuntharapai
A
Lee
J
Hebert
CA
Kim
KJ
Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes.
J Immunol.
153
1994
5682
20
Samanta
AK
Oppenheim
JJ
Matsushima
K
Interleukin 8 (monocyte-derived neutrophil chemotactic factor) dynamically regulates its own receptor expression on human neutrophils.
J Biol Chem.
265
1990
183
21
Khandaker
MH
Mitchell
G
Xu
L
et al
Metalloproteinases are involved in lipopolysaccharide- and tumor necrosis factor-alpha-mediated regulation of CXCR1 and CXCR2 chemokine receptor expression.
Blood.
93
1999
2173
22
Lloyd
AR
Biragyn
A
Johnston
JA
et al
Granulocyte-colony stimulating factor and lipopolysaccharide regulate the expression of interleukin 8 receptors on polymorphonuclear leukocytes.
J Biol Chem.
270
1995
28,188
23
Manna
SK
Samanta
AK
Upregulation of interleukin-8 receptor in human polymorphonuclear neutrophils by formyl peptide and lipopolysaccharide.
FEBS Lett.
367
1995
117
24
Loetscher
M
Gerber
B
Loetscher
P
et al
Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes.
J Exp Med.
184
1996
963
25
Taub
DD
Lloyd
AR
Conlon
K
et al
Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells.
J Exp Med.
177
1993
1809
26
Liao
F
Rabin
RL
Yannelli
JR
Koniaris
LG
Vanguri
P
Farber
JM
Human Mig chemokine: biochemical and functional characterization.
J Exp Med.
182
1995
1301
27
Cole
KE
Strick
CA
Paradis
TJ
et al
Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.
J Exp Med.
187
1998
2009
28
Loetscher
M
Geiser
T
O'Reilly
T
Zwahlen
R
Baggiolini
M
Moser
B
Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.
J Biol Chem.
269
1994
232
29
Feng
Y
Broder
CC
Kennedy
PE
Berger
EA
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see Comments].
Science.
272
1996
872
30
Bleul
CC
Farzan
M
Choe
H
et al
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.
Nature.
382
1996
829
31
Oberlin
E
Amara
A
Bachelerie
F
et al
The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
Nature.
382
1996
833
32
Jourdan
P
Abbal
C
Noraz
N
et al
IL-4 induces functional cell-surface expression of CXCR4 on human T cells.
J Immunol.
160
1998
4153
33
Ma
Q
Jones
D
Borghesani
PR
et al
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice.
Proc Natl Acad Sci U S A.
95
1998
9448
34
Tachibana
K
Hirota
S
Iizasa
H
et al
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.
Nature.
393
1998
591
35
Nagasawa
T
Hirota
S
Tachibana
K
et al
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1.
Nature.
382
1996
635
36
Dobner
T
Wolf
I
Emrich
T
Lipp
M
Differentiation-specific expression of a novel G protein-coupled receptor from Burkitt's lymphoma.
Eur J Immunol.
22
1992
2795
37
Legler
DF
Loetscher
M
Roos
RS
Clark-Lewis
I
Baggiolini
M
Moser
B
B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5.
J Exp Med.
187
1998
655
38
Bazan
JF
Bacon
KB
Hardiman
G
et al
A new class of membrane-bound chemokine with a CX3C motif.
Nature.
385
1997
640
39
Imai
T
Hieshima
K
Haskell
C
et al
Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion.
Cell.
91
1997
521
40
Fong
AM
Robinson
LA
Steeber
DA
et al
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow.
J Exp Med.
188
1998
1413
41
Kanazawa
N
Nakamura
T
Tashiro
K
et al
Fractalkine and macrophage-derived chemokine: T cell-attracting chemokines expressed in T cell area dendritic cells.
Eur J Immunol.
29
1999
1925
42
Neote
K
DiGregorio
D
Mak
JY
Horuk
R
Schall
TJ
Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor.
Cell.
72
1993
415
43
Chee
MS
Satchwell
SC
Preddie
E
Weston
KM
Barrell
BG
Human cytomegalovirus encodes three G protein-coupled receptor homologues.
Nature.
344
1990
774
44
Gao
JL
Murphy
PM
Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor.
J Biol Chem.
269
1994
28,539
45
Ben-Baruch
A
Xu
L
Young
PR
Bengali
K
Oppenheim
JJ
Wang
JM
Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors: C-C CKR1, a receptor for macrophage inflammatory protein-1 alpha/Rantes, is also a functional receptor for MCP3.
J Biol Chem.
270
1995
22,123
46
Combadiere
C
Ahuja
SK
van Damme
J
Tiffany
HL
Gao
JL
Murphy
PM
Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B.
J Biol Chem.
270
1995
29,671
47
Gong
X
Gong
W
Kuhns
DB
Ben-Baruch
A
Howard
OM
Wang
JM
Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors.
J Biol Chem.
272
1997
11,682
48
Tsou
CL
Gladue
RP
Carroll
LA
et al
Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor.
J Exp Med.
188
1998
603
49
Youn
BS
Zhang
SM
Broxmeyer
HE
et al
Characterization of CKbeta8 and CKbeta8-1: two alternatively spliced forms of human beta-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1.
Blood.
91
1998
3118
50
Sica
A
Saccani
A
Borsatti
A
et al
Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes.
J Exp Med.
185
1997
969
51
Zella
D
Barabitskaja
O
Burns
JM
et al
Interferon-gamma increases expression of chemokine receptors CCR1, CCR3, and CCR5, but not CXCR4 in monocytoid U937 cells.
Blood.
91
1998
4444
52
Bonecchi
R
Polentarutti
N
Luini
W
et al
Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils.
J Immunol.
162
1999
474
53
Loetscher
P
Seitz
M
Baggiolini
M
Moser
B
Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes.
J Exp Med.
184
1996
569
54
Perera
LP
Goldman
CK
Waldmann
TA
IL-15 induces the expression of chemokines and their receptors in T lymphocytes.
J Immunol.
162
1999
2606
55
Sozzani
S
Ghezzi
S
Iannolo
G
et al
Interleukin 10 increases CCR5 expression and HIV infection in human monocytes.
J Exp Med.
187
1998
439
56
Yoshimura
T
Leonard
EJ
Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes.
J Immunol.
145
1990
292
57
Van Riper
G
Siciliano
S
Fischer
PA
Meurer
R
Springer
MS
Rosen
H
Characterization and species distribution of high affinity GTP-coupled receptors for human rantes and monocyte chemoattractant protein 1.
J Exp Med.
177
1993
851
58
Yamagami
S
Tokuda
Y
Ishii
K
Tanaka
H
Endo
N
cDNA cloning and functional expression of a human monocyte chemoattractant protein 1 receptor.
Biochem Biophys Res Commun.
202
1994
1156
59
Charo
IF
Myers
SJ
Herman
A
Franci
C
Connolly
AJ
Coughlin
SR
Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails.
Proc Natl Acad Sci U S A.
91
1994
2752
60
Penton-Rol
G
Polentarutti
N
Luini
W
et al
Selective inhibition of expression of the chemokine receptor CCR2 in human monocytes by IFN-gamma.
J Immunol.
160
1998
3869
61
Dahinden
CA
Geiser
T
Brunner
T
et al
Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine.
J Exp Med.
179
1994
751
62
Ponath
PD
Qin
S
Ringler
DJ
et al
Cloning of the human eosinophil chemoattractant, eotaxin: expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils.
J Clin Invest.
97
1996
604
63
Daugherty
BL
Siciliano
SJ
DeMartino
JA
Malkowitz
L
Sirotina
A
Springer
MS
Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
J Exp Med.
183
1996
2349
64
Kitaura
M
Nakajima
T
Imai
T
et al
Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3.
J Biol Chem.
271
1996
7725
65
Uguccioni
M
Mackay
CR
Ochensberger
B
et al
High expression of the chemokine receptor CCR3 in human blood basophils: role in activation by eotaxin, MCP-4, and other chemokines.
J Clin Invest.
100
1997
1137
66
Gerber
BO
Zanni
MP
Uguccioni
M
et al
Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils.
Curr Biol.
7
1997
836
67
Forssmann
U
Uguccioni
M
Loetscher
P
et al
Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes.
J Exp Med.
185
1997
2171
68
Elsner
J
Petering
H
Kluthe
C
et al
Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils.
Eur J Immunol.
28
1998
2152
69
Doranz
BJ
Rucker
J
Yi
Y
et al
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
Cell.
85
1996
1149
70
Power
CA
Meyer
A
Nemeth
K
et al
Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line.
J Biol Chem.
270
1995
19,495
71
Imai
T
Baba
M
Nishimura
M
Kakizaki
M
Takagi
S
Yoshie
O
The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4.
J Biol Chem.
272
1997
15,036
72
Imai
T
Chantry
D
Raport
CJ
et al
Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4.
J Biol Chem.
273
1998
1764
73
D'Ambrosio
D
Iellem
A
Bonecchi
R
et al
Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells.
J Immunol.
161
1998
5111
74
Samson
M
Labbe
O
Mollereau
C
Vassart
G
Parmentier
M
Molecular cloning and functional expression of a new human CC-chemokine receptor gene.
Biochemistry.
35
1996
3362
75
Ruffing
N
Sullivan
N
Sharmeen
L
Sodroski
J
Wu
L
CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells.
Cell Immunol.
189
1998
160
76
Raport
CJ
Gosling
J
Schweickart
VL
Gray
PW
Charo
IF
Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha.
J Biol Chem.
271
1996
17,161
77
Kasahara
T
Makuta
Y
Funakoshi
M
Aizu-Yokota
E
Sonoda
Y
IL-10 increases CCR5 expression in differentiated HL-60 cells through activation of MAPK and STATS [abstract].
1999
First International Congress on Cytokines/Chemokines in Infectious Diseases
Bethesda, MD
78
Baba
M
Imai
T
Nishimura
M
et al
Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC.
J Biol Chem.
272
1997
14,893
79
Liao
F
Rabin
RL
Smith
CS
Sharma
G
Nutman
TB
Farber
JM
CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha.
J Immunol.
162
1999
186
80
Greaves
DR
Wang
W
Dairaghi
DJ
et al
CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells.
J Exp Med.
186
1997
837
81
Yoshida
R
Imai
T
Hieshima
K
et al
Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7.
J Biol Chem.
272
1997
13,803
82
Birkenbach
M
Josefsen
K
Yalamanchili
R
Lenoir
G
Kieff
E
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors.
J Virol.
67
1993
2209
83
Campbell
JJ
Bowman
EP
Murphy
K
et al
6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7.
J Cell Biol.
141
1998
1053
84
Yanagihara
S
Komura
E
Nagafune
J
Watarai
H
Yamaguchi
Y
EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation.
J Immunol.
161
1998
3096
85
Miller
MD
Krangel
MS
The human cytokine I-309 is a monocyte chemoattractant.
Proc Natl Acad Sci U S A.
89
1992
2950
86
Roos
RS
Loetscher
M
Legler
DF
Clark-Lewis
I
Baggiolini
M
Moser
B
Identification of CCR8, the receptor for the human CC chemokine I-309.
J Biol Chem.
272
1997
17,251
87
Napolitano
M
Zingoni
A
Bernardini
G
et al
Molecular cloning of TER1, a chemokine receptor-like gene expressed by lymphoid tissues.
J Immunol.
157
1996
2759
88
Samson
M
Stordeur
P
Labbe
O
Soularue
P
Vassart
G
Parmentier
M
Molecular cloning and chromosomal mapping of a novel human gene, ChemR1, expressed in T lymphocytes and polymorphonuclear cells and encoding a putative chemokine receptor.
Eur J Immunol.
26
1996
3021
89
Zaballos
A
Varona
R
Gutierrez
J
Lind
P
Marquez
G
Molecular cloning and RNA expression of two new human chemokine receptor-like genes.
Biochem Biophys Res Commun.
227
1996
846
90
Tiffany
HL
Lautens
LL
Gao
JL
et al
Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309.
J Exp Med.
186
1997
165
91
Zingoni
A
Soto
H
Hedrick
JA
et al
The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells.
J Immunol.
161
1998
547
92
Horuk
R
Hesselgesser
J
Zhou
Y
et al
The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains.
J Biol Chem.
273
1998
386
93
Zaballos
A
Gutierrez
J
Varona
R
Ardavin
C
Marquez
G
Identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK.
J Immunol.
162
1999
5671
94
Vicari
AP
Figueroa
DJ
Hedrick
JA
et al
TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development.
Immunity.
7
1997
291
95
Bonini
JA
Martin
SK
Dralyuk
F
Roe
MW
Philipson
LH
Steiner
DF
Cloning, expression, and chromosomal mapping of a novel human CC-chemokine receptor (CCR10) that displays high-affinity binding for MCP-1 and MCP-3.
DNA Cell Biol.
16
1997
1249
96
Nibbs
RJ
Wylie
SM
Yang
J
Landau
NR
Graham
GJ
Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6.
J Biol Chem.
272
1997
32,078
97
Yoshida
T
Imai
T
Kakizaki
M
Nishimura
M
Takagi
S
Yoshie
O
Identification of single C motif-1/lymphotactin receptor XCR1.
J Biol Chem.
273
1998
16,551
98
Heiber
M
Docherty
JM
Shah
G
et al
Isolation of three novel human genes encoding G protein-coupled receptors.
DNA Cell Biol.
14
1995
25
99
Kennedy
J
Kelner
GS
Kleyensteuber
S
et al
Molecular cloning and functional characterization of human lymphotactin.
J Immunol.
155
1995
203
100
Giancarlo
B
Silvano
S
Albert
Z
Mantovani
A
Allavena
P
Migratory response of human natural killer cells to lymphotactin.
Eur J Immunol.
26
1996
3238
101
Marsh
WL
Present status of the Duffy blood group system.
CRC Crit Rev Clin Lab Sci.
5
1975
387
102
Chaudhuri
A
Zbrzezna
V
Johnson
C
et al
Purification and characterization of an erythrocyte membrane protein complex carrying Duffy blood group antigenicity: possible receptor for Plasmodium vivax and Plasmodium knowlesi malaria parasite.
J Biol Chem.
264
1989
13,770
103
Chaudhuri
A
Polyakova
J
Zbrzezna
V
Williams
K
Gulati
S
Pogo
AO
Cloning of glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite.
Proc Natl Acad Sci U S A.
90
1993
10,793
104
Darbonne
WC
Rice
GC
Mohler
MA
et al
Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin.
J Clin Invest.
88
1991
1362
105
Neote
K
Darbonne
W
Ogez
J
Horuk
R
Schall
TJ
Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells.
J Biol Chem.
268
1993
12,247
106
Szabo
MC
Soo
KS
Zlotnik
A
Schall
TJ
Chemokine class differences in binding to the Duffy antigen-erythrocyte chemokine receptor.
J Biol Chem.
270
1995
25,348
107
Hadley
TJ
Lu
ZH
Wasniowska
K
et al
Postcapillary venule endothelial cells in kidney express a multispecific chemokine receptor that is structurally and functionally identical to the erythroid isoform, which is the Duffy blood group antigen.
J Clin Invest.
94
1994
985
108
Chaudhuri
A
Nielsen
S
Elkjaer
ML
Zbrzezna
V
Fang
F
Pogo
AO
Detection of Duffy antigen in the plasma membranes and caveolae of vascular endothelial and epithelial cells of nonerythroid organs.
Blood.
89
1997
701
109
Horuk
R
Martin
A
Hesselgesser
J
et al
The Duffy antigen receptor for chemokines: structural analysis and expression in the brain.
J Leukoc Biol.
59
1996
29
110
Hadley
TJ
Peiper
SC
From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen.
Blood.
89
1997
3077
111
Murphy
PM
Chemokine receptors: structure, function and role in microbial pathogenesis.
Cytokine Growth Factor Rev.
7
1996
47
112
Bokoch
GM
Chemoattractant signaling and leukocyte activation.
Blood.
86
1995
1649
113
Wu
D
LaRosa
GJ
Simon
MI
G protein-coupled signal transduction pathways for interleukin-8.
Science.
261
1993
101
114
Kuang
Y
Wu
Y
Jiang
H
Wu
D
Selective G protein coupling by C-C chemokine receptors.
J Biol Chem.
271
1996
3975
115
Bacon
KB
Szabo
MC
Yssel
H
Bolen
JB
Schall
TJ
RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells.
J Exp Med.
184
1996
873
116
Turner
SJ
Domin
J
Waterfield
MD
Ward
SG
Westwick
J
The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha.
J Biol Chem.
273
1998
25,987
117
Huang
R
Lian
JP
Robinson
D
Badwey
JA
Neutrophils stimulated with a variety of chemoattractants exhibit rapid activation of p21-activated kinases (Paks): separate signals are required for activation and inactivation of paks.
Mol Cell Biol.
18
1998
7130
118
Mellado
M
Rodriguez-Frade
JM
Aragay
A
et al
The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor.
J Immunol.
161
1998
805
119
Ganju
RK
Dutt
P
Wu
L
et al
Beta-chemokine receptor CCR5 signals via the novel tyrosine kinase RAFTK.
Blood.
91
1998
791
120
Kampten
GT
Stafford
S
Poulsen
LK
Alam
R
The MAP kinase ERK2 is activated through CC chemokine receptor 3 (CCR3) and is essential for eotaxin-stimulated eosinophil chemotaxis.
J Allergy Exp Immunol.
101
1998
223
121
Lawrence
MB
Springer
TA
Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins.
Cell.
65
1991
859
122
Tanaka
Y
Adams
DH
Shaw
S
Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes.
Immunol Today.
14
1993
111
123
Springer
TA
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.
Cell.
76
1994
301
124
Rot
A
Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism.
Eur J Immunol.
23
1993
303
125
Strieter
RM
Polverini
PJ
Kunkel
SL
et al
The functional role of the ELR motif in CXC chemokine-mediated angiogenesis.
J Biol Chem.
270
1995
27,348
126
Maione
TE
Gray
GS
Petro
J
et al
Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.
Science.
247
1990
77
127
Koch
AE
Polverini
PJ
Kunkel
SL
et al
Interleukin-8 as a macrophage-derived mediator of angiogenesis.
Science.
258
1992
1798
128
Michel
G
Kemeny
L
Peter
RU
et al
Interleukin-8 receptor-mediated chemotaxis of normal human epidermal cells.
FEBS Lett.
305
1992
241
129
Tuschil
A
Lam
C
Haslberger
A
Lindley
I
Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation.
J Invest Dermatol.
99
1992
294
130
Gupta
SK
Singh
JP
Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression.
J Cell Biol.
127
1994
1121
131
Fujisawa
N
Hayashi
S
Kurdowska
A
Carr
FK
Miller
EJ
Inhibition of GROalpha-induced human endothelial cell proliferation by the alpha-chemokine inhibitor antileukinate.
Cytokine.
11
1999
231
132
Schonbeck
U
Brandt
E
Petersen
F
Flad
HD
Loppnow
H
IL-8 specifically binds to endothelial but not to smooth muscle cells.
J Immunol.
154
1995
2375
133
Petzelbauer
P
Watson
CA
Pfau
SE
Pober
JS
IL-8 and angiogenesis: evidence that human endothelial cells lack receptors and do not respond to IL-8 in vitro.
Cytokine.
7
1995
267
134
Gupta
SK
Lysko
PG
Pillarisetti
K
Ohlstein
E
Stadel
JM
Chemokine receptors in human endothelial cells: functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines.
J Biol Chem.
273
1998
4282
135
Volin
MV
Joseph
L
Shockley
MS
Davies
PF
Chemokine receptor CXCR4 expression in endothelium.
Biochem Biophys Res Commun.
242
1998
46
136
Murdoch
C
Monk
PN
Finn
A
CXC chemokine receptor expression on human endothelial cells.
Cytokine.
11
1999
704
137
Murdoch
C
Monk
PN
Finn
A
Functional expression of chemokine receptor CXCR4 on human epithelial cells.
Immunology.
98
1999
36
138
Moscatelli
D
High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells.
J Cell Physiol.
131
1987
123
139
Schroder
JM
Noso
N
Sticherling
M
Christophers
E
Role of eosinophil-chemotactic C-C chemokines in cutaneous inflammation.
J Leukoc Biol.
59
1996
1
140
Standiford
TJ
Kunkel
SL
Greenberger
MJ
Laichalk
LL
Strieter
RM
Expression and regulation of chemokines in bacterial pneumonia.
J Leukoc Biol.
59
1996
24
141
Kunkel
SL
Lukacs
N
Kasama
T
Strieter
RM
The role of chemokines in inflammatory joint disease.
J Leukoc Biol.
59
1996
6
142
Lukacs
NW
Kunkel
SL
Chemokines and their role in disease.
Int J Clin Lab Res.
28
1998
91
143
Schulz
BS
Michel
G
Wagner
S
et al
Increased expression of epidermal IL-8 receptor in psoriasis: down-regulation by FK-506 in vitro.
J Immunol.
151
1993
4399
144
Lemster
BH
Carroll
PB
Rilo
HR
Johnson
N
Nikaein
A
Thomson
AW
IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy.
Clin Exp Immunol.
99
1995
148
145
Ross
R
Cell biology of atherosclerosis.
Ann Rev Physiol.
57
1995
791
146
Nelken
NA
Coughlin
SR
Gordon
D
Wilcox
JN
Monocyte chemoattractant protein-1 in human atheromatous plaques.
J Clin Invest.
88
1991
1121
147
Gosling
J
Slaymaker
S
Gu
L
et al
MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B.
J Clin Invest.
103
1999
773
148
Gu
L
Okada
Y
Clinton
SK
et al
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice.
Mol Cell.
2
1998
275
149
Boring
L
Gosling
J
Cleary
M
Charo
IF
Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis.
Nature.
394
1998
894
150
Han
KH
Tangirala
RK
Green
SR
Quehenberger
O
Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes: a regulatory role for plasma LDL.
Arterioscler Thromb Vasc Biol.
18
1998
1983
151
Weber
C
Draude
G
Weber
KS
Wubert
J
Lorenz
RL
Weber
PC
Downregulation by tumor necrosis factor-alpha of monocyte CCR2 expression and monocyte chemotactic protein-1-induced transendothelial migration is antagonized by oxidized low-density lipoprotein: a potential mechanism of monocyte retention in atherosclerotic lesions.
Atherosclerosis.
145
1999
115
152
Schecter
AD
Rollins
BJ
Zhang
YJ
et al
Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells.
J Biol Chem.
272
1997
28,568
153
Hayes
IM
Jordan
NJ
Towers
S
et al
Human vascular smooth muscle cells express receptors for CC chemokines.
Arterioscler Thromb Vasc Biol.
18
1998
397
154
Reape
TJ
Rayner
K
Manning
CD
et al
Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques.
Am J Pathol.
154
1999
365
155
Wang
X
Yue
TL
Ohlstein
EH
Sung
CP
Feuerstein
GZ
Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response.
J Biol Chem.
271
1996
24,286
156
Yue
TL
Wang
X
Sung
CP
et al
Interleukin-8: a mitogen and chemoattractant for vascular smooth muscle cells.
Circ Res.
75
1994
1
157
Boisvert
WA
Santiago
R
Curtiss
LK
Terkeltaub
RA
A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice.
J Clin Invest.
101
1998
353
158
Kita
H
Gleich
GJ
Chemokines active on eosinophils: potential roles in allergic inflammation.
J Exp Med.
183
1996
2421
159
Lukacs
NW
Strieter
RM
Chensue
SW
Kunkel
SL
Activation and regulation of chemokines in allergic airway inflammation.
J Leukoc Biol.
59
1996
13
160
Griffiths-Johnson
DA
Collins
PD
Jose
PJ
Williams
TJ
Animal models of asthma: role of chemokines.
Methods Enzymol.
288
1997
241
161
Kay
AA
Corrigan
CJ
Asthma, eosinophils and neutrophils.
Br Med Bull.
48
1992
51
162
Taha
RA
Minshall
EM
Miotto
D
et al
Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and nonasthmatic individuals.
J Allergy Clin Immunol.
103
1999
476
163
Ying
S
Robinson
DS
Meng
Q
et al
Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma: association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells.
Eur J Immunol.
27
1997
3507
164
Zeibecoglou
K
Ying
S
Yamada
T
et al
Increased mature and immature CCR3 messenger RNA+ eosinophils in bone marrow from patients with atopic asthma compared with atopic and nonatopic control subjects.
J Allergy Clin Immunol.
103
1999
99
165
Zimmermann
N
Bernstein
JA
Rothenberg
ME
Polymorphisms in the human CC chemokine receptor-3 gene.
Biochim Biophys Acta.
1442
1998
170
166
Gavett
SH
Chen
X
Finkelman
F
Wills-Karp
M
Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia.
Am J Respir Cell Mol Biol.
10
1994
587
167
Jiang
Y
Salafranca
MN
Adhikari
S
et al
Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis.
J Neuroimmunol.
86
1998
1
168
Miller
LH
Mason
SJ
Dvorak
JA
McGinniss
MH
Rothman
IK
Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants.
Science.
189
1975
561
169
Nichols
ME
Rubinstein
P
Barnwell
J
Rodriguez
D
Cordoba
S
Rosenfield
RE
A new human Duffy blood group specificity defined by a murine monoclonal antibody: immunogenetics and association with susceptibility to Plasmodium vivax.
J Exp Med.
166
1987
776
170
Barnwell
JW
Nichols
ME
Rubinstein
P
In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by Plasmodium vivax.
J Exp Med.
169
1989
1795
171
Horuk
R
Chitnis
CE
Darbonne
WC
et al
A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor.
Science.
261
1993
1182
172
Tournamille
C
Le Van Kim
C
Gane
P
Cartron
JP
Colin
Y
Molecular basis and PCR-DNA typing of the Fya/fyb blood group polymorphism.
Hum Genet.
95
1995
407
173
Iwamoto
S
Omi
T
Kajii
E
Ikemoto
S
Genomic organization of the glycoprotein D gene: Duffy blood group Fya/Fyb alloantigen system is associated with a polymorphism at the 44-amino acid residue.
Blood.
85
1995
622
174
Tournamille
C
Colin
Y
Cartron
JP
Le Van Kim
C
Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals.
Nat Genet.
10
1995
224
175
Cocchi
F
DeVico
AL
Garzino-Demo
A
Arya
SK
Gallo
RC
Lusso
P
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.
Science.
270
1995
1811
176
Deng
H
Liu
R
Ellmeier
W
et al
Identification of a major co-receptor for primary isolates of HIV-1.
Nature.
381
1996
661
177
Dragic
T
Litwin
V
Allaway
GP
et al
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
Nature.
381
1996
667
178
Alkhatib
G
Combadiere
C
Broder
CC
et al
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
Science.
272
1996
1955
179
Doms
RW
Peiper
SC
Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry.
Virology.
235
1997
179
180
Choe
H
Martin
KA
Farzan
M
Sodroski
J
Gerard
NP
Gerard
C
Structural interactions between chemokine receptors, gp120 Env and CD4.
Semin Immunol.
10
1998
249
181
Berger
EA
Murphy
PM
Farber
JM
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
Annu Rev Immunol.
17
1999
657
182
Wu
L
Gerard
NP
Wyatt
R
et al
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
Nature.
384
1996
179
183
Wang
WK
Dudek
T
Zhao
YJ
Brumblay
HG
Essex
M
Lee
TH
CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.
Proc Natl Acad Sci U S A.
95
1998
5740
184
Rabut
GE
Konner
JA
Kajumo
F
Moore
JP
Dragic
T
Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1.
J Virol.
72
1998
3464
185
Farzan
M
Mirzabekov
T
Kolchinsky
P
et al
Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.
Cell.
96
1999
667
186
Chan
DC
Fass
D
Berger
JM
Kim
PS
Core structure of gp41 from the HIV envelope glycoprotein.
Cell.
89
1997
263
187
Endres
MJ
Clapham
PR
Marsh
M
et al
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.
Cell.
87
1996
745
188
Connor
RI
Sheridan
KE
Ceradini
D
Choe
S
Landau
NR
Change in coreceptor use correlates with disease progression in HIV-1–infected individuals.
J Exp Med.
185
1997
621
189
Liu
R
Paxton
WA
Choe
S
et al
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
Cell.
86
1996
367
190
Samson
M
Libert
F
Doranz
BJ
et al
Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.
Nature.
382
1996
722
191
Biti
R
French
R
Young
J
Bennetts
B
Stewart
G
Liang
T
HIV-1 infection in an individual homozygous for the CCR5 deletion allele.
Nat Med.
3
1997
252
192
Lee
B
Doranz
BJ
Rana
S
et al
Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4.
J Virol.
72
1998
7450
193
Ansari-Lari
MA
Liu
XM
Metzker
ML
Rut
AR
Gibbs
RA
The extent of genetic variation in the CCR5 gene.
Nat Genet.
16
1997
221
194
Moriruchi
H
Moriruchi
M
HTLV-1 Tax transactivates promoters for CXCR4 and CCR5, co-receptors for HIV-1 entry [abstract].
1999
First International Congress on Cytokines/Chemokines in Infectious Diseases
Bethesda, MD